Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

DNA alkylating drugs have been used as cancer chemotherapy with variable outcomes. The establishment of predictive biomarkers to identify patients who will effectively respond to treatment would allow for the development of personalized therapies. As the degree of interaction of alkylating drug with DNA plays a key role in their mechanism of action, our hypothesis is that the measurement of the DNA adducts formed by alkylating drugs could be used to inform patient stratification. Beginning with busulfan, we took advantage of our DNA adductomic approach to characterize DNA adducts formed by reacting busulfan with calf-thymus DNA. Samples collected from six patients undergoing busulfan-based chemotherapy prior to allogeneic hematopoietic cell transplantation were analyzed for the presence of busulfan-derived DNA adducts. Among the 15 adducts detected in vitro, 12 were observed in the patient blood confirming the presence of a large profile of DNA adducts in vivo. Two of the detected adducts were structurally confirmed by comparison with synthetic standards and quantified in patients. These data confirm our ability to comprehensively characterize busulfan-derived DNA damage and set the stage for the development of methods to support personalized chemotherapy.

Original languageEnglish (US)
Pages (from-to)197-210
Number of pages14
JournalMolecular Therapy Oncolytics
Volume28
DOIs
StatePublished - Mar 16 2023

Bibliographical note

Funding Information:
MS was carried out in the Analytical Biochemistry Shared Resource of the Masonic Cancer Center, University of Minnesota, supported in part by Cancer Center Support Grant CA-077598 . Salary support for P.W.V., head of the Analytical Biochemistry Shared Resource, was provided by the National Cancer Institute Grant CA-211256 . The authors would like to thank Dr. Laura Maertens and Carsten Spry for their help with initiating and coordinating the sample collection for this study. We also wish to thank the patients for their participation in this study. Additionally, we acknowledge the hard work and dedication of the nurses and other medical personnel of the M Health Fairview University of Minnesota Medical Center for their help with collecting the samples. We thank Robert Carlson for editorial assistance.

Publisher Copyright:
© 2023 The Authors

Keywords

  • DNA adduct
  • alkylating agents
  • biomarker
  • busulfan
  • mass spectrometry
  • precision medicine

Fingerprint

Dive into the research topics of 'Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy'. Together they form a unique fingerprint.

Cite this